Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;18(2):e70058.
doi: 10.1002/jfa2.70058.

Follow-Up Magnetic Resonance Imaging in Monitoring Charcot Foot and Its Association With Total Contact Cast Treatment Duration and Long-Term Outcomes: A Retrospective Cohort Study

Johan Schoug  1   2 , Per Katzman  1   2 , Erik Uddman  1   2 , Magnus Löndahl  1   2
Affiliations

Follow-Up Magnetic Resonance Imaging in Monitoring Charcot Foot and Its Association With Total Contact Cast Treatment Duration and Long-Term Outcomes: A Retrospective Cohort Study

Johan Schoug et al. J Foot Ankle Res. 2025 Jun.

Abstract

Aims/hypothesis: Charcot foot (CF), a potentially debilitating complication of neuropathy, requires offloading to avoid foot deformities. Follow-up MRI examinations are often used to determine the optimal duration of total contact cast (TCC) offloading treatment. This study investigated the use of follow-up MRI during CF treatment and its relationship to offloading duration and risk of future surgery.

Methods: People with diabetes mellitus and MRI-confirmed CF treated at Skåne University Hospital (Lund and Malmö, Sweden) between 2006 and 2022 were studied retrospectively. Individuals monitored with follow-up MRI examinations were compared with those who only underwent diagnostic MRI. A regression model was applied to evaluate factors predicting TCC and total CF treatment duration.

Results: One-hundred and twenty-two individuals (45 [37%] DM1; 47 [39%] women; median age 60 [IQR 53-68] years) with a total of 143 CF events were included. 76 (53%) of these CF events were monitored using a total of 141 follow-up MRI examinations. Individuals monitored with MRI had significantly longer TCC and total CF treatment durations (p < 0.001). Individual characteristics (with the exception of sex), rate of stage 1 CF, and risk of future surgery did not differ between the two groups and only use of follow-up MRI (p < 0.001) remained a significant predictor of both longer TCC and total CF treatment durations in a regression model.

Conclusions/interpretation: In this retrospective cohort study, use of follow-up MRI was associated with longer TCC and total treatment times despite similar characteristics and outcomes. Prospective studies are needed to further elucidate the optimal use of MRI in monitoring CF.

Keywords: Charcot arthropathy; cohort; diabetic foot; magnetic resonance imaging; treatment.

PubMed Disclaimer

Conflict of interest statement

Until April 2024, M.L. has been on the speakers’ list and has received consultant fees from Abbott, Amgen Inc, AstraZeneca, Bayer, Boehringer‐Ingelheim, Eli Lilly and Company, Merck, Novartis, Novo Nordisk and Sanofi. M.L. has received unrestricted research grants from Boehringer‐Ingelheim and Sanofi. From May 2024, M.L. is an employee of Eli Lilly and Company. J.S. has nothing to disclose. P.K. has nothing to disclose. E.U. is on the speakers’ list for Eli Lilly and Company.

Figures

FIGURE 1
FIGURE 1
Flow chart of the inclusion of individuals in the study.
FIGURE 2
FIGURE 2
Risk of partial amputation after initiated CF treatment, divided according to the use of follow‐up MRI examinations (blue, follow‐up MRI group; red, no follow‐up MRI group).
See this image and copyright information in PMC

References

    1. Rogers L. C., Frykberg R. G., Armstrong D. G., et al., “The Charcot Foot in Diabetes,” Diabetes Care 34, no. 9 (2011): 2123–2129, 10.2337/dc11-0844. - DOI - PMC - PubMed
    1. Wukich D. K., Sung W., Wipf S. A. M., and Armstrong D. G., “The Consequences of Complacency: Managing the Effects of Unrecognized Charcot Feet,” Diabetic Medicine 28, no. 2 (2011): 195–198, 10.1111/j.1464-5491.2010.03141.x. - DOI - PubMed
    1. Chantelau E., “The Perils of Procrastination: Effects of Early vs. Delayed Detection and Treatment of Incipient Charcot Fracture,” Diabetic Medicine 22, no. 12 (2005): 1707–1712, 10.1111/j.1464-5491.2005.01677.x. - DOI - PubMed
    1. Schoug J., Katzman P., Fagher K., and Löndahl M., “Charcot Foot Offloading in Stage 0 Is Associated With Shorter Total Contact Cast Treatment and Lower Risk of Recurrence and Reconstructive Surgery: A Pilot Study,” Diabetes Care 47, no. 2 (2024): 252–258, 10.2337/dc23-1063. - DOI - PubMed
    1. Bittante C., Cerasari V., Bellizzi E., et al., “Early Treatment of Acute Stage 0/1 Diabetic Charcot Foot Can Avoid Major Amputations at One Year,” Journal of Clinical Medicine 13, no. 6 (2024): 1633, 10.3390/jcm13061633. - DOI - PMC - PubMed